TriSalus Life Sciences IncNASDAQ:TLSI
- LAST PRICE9.3100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots9.3000/ 1
- Ask / Lots11.0000/ 25
- Open / Previous Close9.4900 / 9.3100
- Day Range
- 52 Week Range
- Volume27,289
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TLSI |
|---|---|---|
| 09:32 ET | 510 | 9.49 |
| 10:08 ET | 3624 | 9.52 |
| 10:15 ET | 500 | 9.505 |
| 11:00 ET | 1105 | 9.46 |
| 11:04 ET | 718 | 9.37 |
| 11:24 ET | 100 | 9.37 |
| 11:58 ET | 100 | 9.42 |
| 12:00 ET | 215 | 9.37 |
| 12:32 ET | 3655 | 9.37 |
| 12:38 ET | 300 | 9.3501 |
| 12:48 ET | 600 | 9.37 |
| 12:52 ET | 2465 | 9.31 |
| 12:54 ET | 1151 | 9.327 |
| 12:59 ET | 100 | 9.33 |
| 01:17 ET | 100 | 9.31 |
| 01:39 ET | 100 | 9.33 |
| 01:46 ET | 2717 | 9.31 |
| 02:08 ET | 100 | 9.31 |
| 02:36 ET | 100 | 9.31 |
| 02:38 ET | 400 | 9.35 |
| 03:09 ET | 200 | 9.3135 |
| 03:12 ET | 200 | 9.33 |
| 03:21 ET | 270 | 9.31 |
| 03:32 ET | 100 | 9.33 |
| 03:54 ET | 271 | 9.31 |
| 03:57 ET | 100 | 9.31 |
| 03:59 ET | 119 | 9.31 |
Yesterday
Apr 1, 2024
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update, from 8:00AM ET on Monday Apr 01, 2024 by Dow Jones
8:00AM ET on Monday Apr 01, 2024 by Dow JonesPress Release: TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update, from 8:00AM ET on Monday Apr 01, 2024 by Dow Jones
8:00AM ET on Monday Apr 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
TriSalus Life Sciences Inc | 249.1M | -5.1x | --- |
Fennec Pharmaceuticals Inc | 248.8M | -15.0x | --- |
AC Immune SA | 246.0M | -3.6x | --- |
Werewolf Therapeutics Inc | 270.5M | -5.7x | --- |
Uniqure NV | 211.0M | -0.7x | --- |
Mediwound Ltd | 176.6M | -25.1x | --- |
Company Information
TriSalus Life Sciences, Inc. is an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. The Company’s platform includes devices that utilize a drug delivery technology and a clinical stage investigational immunotherapy. The Company’s two FDA-cleared devices use its Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. SD-101, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment. Patient data generated during Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that SD-101 delivered through PEDD may has favorable immune effects on the liver and systemically.
Contact Information
- Headquarters
- 6272 West 91St AvenueWESTMINSTER, CO, United States 80031
- Phone
- 415-336-8917
- Fax
- 302-636-5454
Executives
- Independent Non-Executive Chairman of the Board
- Mats Wahlstrom
- President, Chief Executive Officer, Director
- Mary Szela
- Chief Financial Officer, Director
- Sean Murphy
- President - Device Technology
- James Alecxih
- Senior Vice President - Corporate Development & Strategy
- Richard Marshak
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $249.1M |
|---|---|
Revenue (TTM) | $18.5M |
Shares Outstanding | 26.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.84 |
Book Value | $-0.98 |
P/E Ratio | -5.1x |
Price/Sales (TTM) | 13.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -292.54% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
